Your browser doesn't support javascript.
loading
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial.
Copland, Mhairi; Slade, Daniel; McIlroy, Graham; Horne, Gillian; Byrne, Jenny L; Rothwell, Kate; Brock, Kristian; De Lavallade, Hugues; Craddock, Charles; Clark, Richard E; Smith, Matthew L; Fletcher, Rachel; Bishop, Rebecca; Milojkovic, Dragana; Yap, Christina.
Affiliation
  • Copland M; Paul O'Gorman Leukaemia Research Centre, College of Medical, Veterinary and Life Sciences, Institute of Cancer Sciences, University of Glasgow, Gartnavel General Hospital, Glasgow, UK. Electronic address: mhairi.copland@glasgow.ac.uk.
  • Slade D; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
  • McIlroy G; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
  • Horne G; Paul O'Gorman Leukaemia Research Centre, College of Medical, Veterinary and Life Sciences, Institute of Cancer Sciences, University of Glasgow, Gartnavel General Hospital, Glasgow, UK.
  • Byrne JL; Department of Clinical Haematology, Nottingham University Hospitals, Nottingham, UK.
  • Rothwell K; Department of Clinical Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Brock K; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
  • De Lavallade H; Department of Haemato-oncology, King's College Hospital, London, UK.
  • Craddock C; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK.
  • Clark RE; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
  • Smith ML; Department of Haemato-Oncology, St Bartholomew's Hospital, London, UK.
  • Fletcher R; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
  • Bishop R; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
  • Milojkovic D; Department of Haematology, Imperial College, London, UK.
  • Yap C; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.
Lancet Haematol ; 9(2): e121-e132, 2022 Feb.
Article in En | MEDLINE | ID: mdl-34906334
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials / Guideline / Prognostic_studies Limits: Adolescent / Adult / Female / Humans / Male Language: En Journal: Lancet Haematol Year: 2022 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials / Guideline / Prognostic_studies Limits: Adolescent / Adult / Female / Humans / Male Language: En Journal: Lancet Haematol Year: 2022 Type: Article